. 2022 Apr 28;8(6):879–886. doi: 10.1001/jamaoncol.2022.0864

Table 4. Distribution of Favorable Reporting of Quality-of-Life Outcomes by Industry Sponsorship and Drug Class^a.

Characteristic	Quality-of-life outcomes, No. of trials
Characteristic	Favorable	Accurate
Drug class
Cytotoxic	4	7
Targeted	10	8
Immunotherapy	1	0
Other (repurposed drugs)	1	3
Industry sponsorship
Yes	15	10
No	1	8

^{^a}

Of the 45 included trials, 34 had unimproved quality-of-life outcomes.

Table 4. Distribution of Favorable Reporting of Quality-of-Life Outcomes by Industry Sponsorship and Drug Classa.